EGFR and non-small cell lung carcinoma: To confirm that Gefitinib was affecting its intended molecular targets in these mice, the relative expression of total phospho-EGFR, phospho-ERK and phospho-AKT levels in the four investigated NSCLC tumors was evaluated by Western blot analysis.